Evidence map›Paper›PMID 33189613›Full record

ReviewInternational immunopharmacology2021

Exploring the multifocal therapeutic approaches in COVID-19: A ray of hope.

Arun Kumar, Asmita Deka Dey, Tapan Behl, Swati Chadha, Vishal Aggarwal

Abstract readReview
In one paragraph

Review in International immunopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Arun KumarChitkara College of Pharmacy, Chitkara University, Punjab, India. Electronic address: arundhiman431@gmail.com.
Asmita Deka DeyChitkara College of Pharmacy, Chitkara University, Punjab, India.
Tapan BehlChitkara College of Pharmacy, Chitkara University, Punjab, India.
Swati ChadhaChitkara College of Pharmacy, Chitkara University, Punjab, India.
Vishal AggarwalChitkara College of Pharmacy, Chitkara University, Punjab, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ongoing global pandemic of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is marked as one of the most challenging infectious diseases in the history of mankind with affliction of ~29,737,453 confirmed cases globally. Looking at the present scenario where there is a parallel increment in curve with time, there is an utmost emergency to discover a perennial solution to this life-threatening virus which has led the Human race in an unusual state of affair. The entire health care fraternity is engaged in endeavouring an ultimate way out to hit this pandemic but no such research made till now has been approved yet, to have the potential to bring an end to this fatal situation. Although a few possible treatment choices exist at the moment yet the requirement to search for a still better therapeutic option remains persistent. Global laboratories are working day and night in search for an effective vaccine, many are undergoing clinical trials but their commercialization is no less than a year away. The present review highlights the current potential therapies viz., vaccines, immunotherapies, convulsant plasma therapies, corticosteroids, antithrombotic, intravenous immunoglobulins, nocturnal oxygen therapy etc. that may prove beneficial in attenuating the pandemic situation. However, comparison and presentation of collective data on the therapeutic advancements in mitigating the pandemic situation needs further clinical investigations in order to prove boon to mankind.

Indexed as

Adrenal Cortex HormonesAnticoagulantsCOVID-19COVID-19 SerotherapyCOVID-19 VaccinesDelivery of Health CareHumansHyperbaric OxygenationImmunization, PassiveImmunoglobulins, IntravenousImmunotherapyPandemicsSARS-CoV-2Adrenal Cortex HormonesAnticoagulantsCOVID-19 VaccinesImmunoglobulins, IntravenousCOVID-19Effective therapiesRadiotherapySafetyVaccines

Identifiers

PMID33189613
PMCPMC7608010

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.